NCT03416244View on ClinicalTrials.gov

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions
Esophageal CancerOesophageal CancerOesophageal Cancer MetastaticEsophageal Cancer MetastaticEsophageal Cancers NOSOesophageal Cancer NosGastroEsophageal CancerGastrooesophageal Cancer
Interventions
DRUG

Nivolumab

Nivolumab 240 mg IV fixed dose every two weeks

DRUG

Ipilimumab

Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)

Trial Locations (1)

68167

Universitätsmedizin Mannheim, Heidelberg University, II. Medizinische Klinik, Mannheim

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER